lack of accrual

The combination of clofarabine and cytarabine is an effective and reasonably well-tolerated treatment regimen in patients with either relapsed/refractory or newly diagnosed AML. For this prospective study, we propose the use of clofarabine and cytarabine for second course induction therapy for patients with persistent AML after treatment with an anthracycline and cytarabine.

The primary objective of this prospective study is to evaluate the efficacy (i.e., complete response rate) of clofarabine and cytarabine as second course therapy for the treatment of AML. The secondary objectives are to assess the treatment-related toxicities, to determine the overall and relapse-free survival for patients with AML who are treated with this regimen, and to evaluate potential factors that are predictive of response.

The investigational nature and objective of this study, the procedures involved and their associated risks, potential benefits, and potential alternative therapies will be explained to the patient, and a signed informed consent document will be obtained. Once consented, eligible patients will be treated by the acute leukemia service on the University of Pittsburgh Cancer Institute inpatient unit.

Prior to the start of chemotherapy, patients will receive dexamethasone and ondansetron as pre-medication. Clofarabine will then be administered as intravenous infusion on days 1 through 5. Patients will be monitored closely with vital signs. Cytarabine will then be given as intravenous infusion, starting 3 (maximum of 4) hours after the completion of clofarabine administration on days 1 through 5.

Inclusion Criteria:

1. Patients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine
2. Able to understand and have the ability to provide written informed consent
3. Patients over 18 years of age
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
5. Left ventricular ejection fraction (LVEF) ≥ 50%
6. Negative urine pregnancy test for all females
7. All subjects must agree to use an effective method of contraception while receiving the study drugs

Exclusion Criteria:

1. Diagnosis of acute promyelocytic leukemia
2. Relapsed AML
3. Prior use of clofarabine
4. Previous allogeneic or autologous hematopoietic cell transplantation
5. Impaired liver function (serum total bilirubin > 2.0 mg/dL, alanine aminotransferase and aspartate aminotransferase ≥ 4 x the upper limit of normal)
6. Impaired renal function (serum creatinine ≥ 2.0 mg/dL)
7. Uncontrolled or life-threatening infection that is not responding to antimicrobial therapy
8. History of a psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent
9. Concurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated
10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)

Patients with newly diagnosed AML based on the WHO classification, who have persistent disease after their first course treatment with an anthracycline and cytarabine.

Results data is not available for Overall Survival, Relapse-free Survival, or assessment of potential predictive factors for response to treatment, due to early termination leading to small numbers of subjects analyzed.